Molecular structure of Sulindac, CAS Number: 38194-50-2
Sulindac (CAS 38194-50-2)
See product citations (3)
Alternate Names:
MK-231; (1Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]-indene-3-acetic acid
Application:
Sulindac is an inhibitor of the NF-κB pathway and a Cox inhibitor
CAS Number:
38194-50-2
Purity:
≥98%
Molecular Weight:
356.41
Molecular Formula:
C20H17FO3S
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Sulindac is extensively studied in its effects on cellular signaling pathways and gene expression. Sulindac is employed in investigations to understand the mechanisms by which it influences the pathways involved in cellular proliferation and apoptosis. Sulindac is also a focal point in studies related to its impact on enzyme inhibition, particularly in the modulation of cyclooxygenase enzymes. In the field of chemistry, Sulindac is studied for its stability under various conditions, assisting in the development of methods to enhance the stability of related compounds in laboratory applications.
Sulindac (CAS 38194-50-2) References
- Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. | Taylor, MT., et al. 2000. Cancer Res. 60: 6607-10. PMID: 11118042
- Sulindac and its derivatives: a novel class of anticancer agents. | Haanen, C. 2001. Curr Opin Investig Drugs. 2: 677-83. PMID: 11569947
- Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors. | Li, X., et al. 2015. BMC Cancer. 15: 974. PMID: 26673922
- Diverse amide analogs of sulindac for cancer treatment and prevention. | Mathew, B., et al. 2017. Bioorg Med Chem Lett. 27: 4614-4621. PMID: 28935266
- Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor. | Sung, JW., et al. 2020. Pharm Res. 37: 44. PMID: 31993760
- Chemical and biological studies on indomethacin, sulindac and their analogs. | Shen, TY. and Winter, CA. 1977. Adv Drug Res. 12: 90-245. PMID: 343530
- Sulindac Improves Stiffness and Quality of Life in Women Taking Aromatase Inhibitors for Breast Cancer. | Martinez, JA., et al. 2022. Breast Cancer Res Treat. 192: 113-122. PMID: 35039952
- Photoisomerization of Sulindac and Ozagrel Hydrochloride by Vitamin B2 Catalyst Under Visible Light Irradiation. | Suga, M., et al. 2022. Pharm Res. 39: 577-586. PMID: 35233730
- Sulindac hepatotoxicity: a case report and review. | Gallanosa, AG. and Spyker, DA. 1985. J Toxicol Clin Toxicol. 23: 205-38. PMID: 3903180
- Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. | Duggan, DE. 1981. Drug Metab Rev. 12: 325-37. PMID: 7040018
- Sulindac-induced anaphylaxis. | Burrish, GF. and Kaatz, BL. 1981. Ann Emerg Med. 10: 154-5. PMID: 7469157
- Sulindac therapy of colorectal polyps in familial adenomatous polyposis. | Tonelli, F., et al. 1994. Dig Dis. 12: 259-64. PMID: 7882547
- Clinical pharmacokinetics of sulindac. A dynamic old drug. | Davies, NM. and Watson, MS. 1997. Clin Pharmacokinet. 32: 437-59. PMID: 9195115
Inhibitor of:
β-glucuronidase, 9530003J23Rik, AADAC, AADACL1, ABCC12, ADAR2, AKR1C12, AKR1C13, AKR1C14, AKR1C18, AKR1C19, AKR1C20, AKR1CL1, AKR1CL2, AMDHD1, BC048943, BTR1, C/EBP ε, C6, carbonyl reductase 2, CCDC126, CD62L ligand, CEACAM5, CLCA3_Clac3, Colorectal Adenocarcinoma Marker, Colorectal Carcinoma, Cox-2, CTGLF, CTGLF7, CTL2, Cyp2c54, DBX1, Differentiated Endothelial Cell Marker, DUXA, EG668379, FAM3D, Fe65, FMO4, Fsbp, GCS-α-3, GPR87, HCC-1, HEATR5B, HPRG, IFRG15, ITF, Jagged1, LET-60 RAS, LGALS9, LOC100041263, LOC727844, MAGE-6, Mdr-2, MRGE, NALP1, NALP4f, NAT-1, NPIPL3, pan-Cytokeratin, PAT2, PGD synthase, PGE synthase 2, PGS1, PIGF, PlGF, PlGF2, Pygopus 2, R-Ras, RASL11A, RASL11B, Reg IV, S-100A2, SAA1, SAA3, SAPCD2, SDAD1, SHISA3, TC 21, TSARG4, vasostatin I, vasostatin II, Wnt-3, Ym1, ZNF217, and ZNF659.Activator of:
2610208M17Rik, A33, ABCC11, AKR1C19, AKR1C6, Annexin V, APC, APRIL, Axin, Baxα, BY080835, C18orf34, C1orf181, C330021F23Rik, cryptdin 22, cryptdin 24, cryptdin 25, cryptdin 26, Dapper2, DENND2C, Dvl-3, Elastase-3B, FMO1, FMO2, FMO3, FMO5, frizzled-9, GSDMC4, LIN-15A, LOC100039269, LOC100041139, LOC100041253, MRP4, MRP5, MRP6, Mucin 2, nm23-H1, NORRIN, p130, PAO, Pdcd2L, PEN-2, RT1-B, Spaca6, TAPBPL, TG1019, TMEM118, TRAIL, Wnt-7b, WRM-1, and XKR8.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Sulindac, 1 g | sc-202823 | 1 g | $32.00 | |||
Sulindac, 5 g | sc-202823A | 5 g | $86.00 | |||
Sulindac, 10 g | sc-202823B | 10 g | $150.00 |